DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Transcript

Why It Matters

The results validate ADMA’s differentiated product mix and manufacturing efficiencies, signaling a durable earnings engine that could outpace the broader plasma‑derived therapeutics market. Investors and partners will view the expanded supply network and leadership transition as catalysts for continued revenue acceleration and shareholder value creation.

Key Takeaways

• Revenue $510M, up 20% YoY, driven by Ascentive.
• Gross margin rose to 57.4%, aided by yield‑enhanced production.
• 2026 guidance targets >$635M revenue, $360M adjusted EBITDA.
• Plasma supply expanded to 280 centers, securing long‑term input.
• New CFO Terry Kohler focuses on working‑capital optimization.

Pulse Analysis

ADMA Biologics’ 2025 performance underscores a broader shift in the plasma‑derived therapeutics sector toward specialty, high‑margin products. Ascentive, the company’s patented IVIG, now accounts for roughly 70% of sales, delivering pricing power that eclipses standard immunoglobulins. This product‑centric strategy, combined with a vertically integrated supply chain, has allowed ADMA to capture a larger share of the growing U.S. immune‑globulin market, where demand is buoyed by an aging population and expanding indications for primary humoral immunodeficiency.

The transition of Yield NHANZE technology into routine commercial production represents a structural cost advantage. By extracting more therapeutic protein per plasma unit, ADMA has lifted its gross margin from 51.5% to 57.4% and achieved a 10‑percentage‑point improvement in the fourth‑quarter margin. This manufacturing efficiency not only strengthens profitability but also enhances supply resilience, a critical factor as the industry grapples with plasma collection constraints. The recent diversification of plasma sources to over 280 centers further mitigates sourcing risk and supports long‑term capacity planning.

Looking ahead, ADMA’s forward‑looking guidance—projecting revenue above $1.1 billion and adjusted EBITDA exceeding $700 million by 2029—reflects confidence in sustained Ascentive adoption, continued mix shift, and operational leverage. The leadership change, with Terry Kohler assuming the CFO role, adds expertise in working‑capital optimization, likely accelerating cash conversion and supporting strategic investments such as the SG001 pipeline. Collectively, these factors position ADMA as a compelling growth story for investors seeking exposure to high‑margin biologics with a defensible market position.